Skip to Content

Akers Biosciences, Inc. (AKER)

Corporate Governance / Derivative

  • Date:
  • 11/21/2018
  • Company Name:
  • Akers Biosciences, Inc.
  • Stock Symbol:
  • AKER
  • Status:
  • Pending

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Akers Biosciences, Inc. (NASDAQ: AKER) on behalf of long-term stockholders. Our investigation concerns whether the board of directors of Akers has breached their fiduciary duties to the company. 

The investigation concerns violations arising from a class action lawsuit filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Akers Biosciences, Inc. (NASDAQ: AKER) securities between May 15, 2017 and June 5, 2018 (the “Class Period”).

The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that (1) Akers was improperly recognizing revenue for the fiscal year ended December 31, 2017; (2) Akers downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses; and (3) as a result, defendants' statements about Akers' business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.  The complaint claims that when the truth was revealed to the market, investors suffered damages.

If you are a long term holder of Akers Biosciences securities, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please fill out the form below. 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Akers Biosciences. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: